telisotuzumab
abbvie
[]
#asco22 key slide here for teliso-v. previously reported that squamous cohort met futility (rr 11.1%) and here, #egfr mt cohort also at futility. in egfr wt cohort, efficacy seen (cmet high, rr 52%). 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him